

# Interpretive Diagnostic Error Reduction in Surgical Pathology and Cytology


Guideline from the College of American Pathologists (CAP) Pathology and Laboratory Quality Center and the Association of Directors of Anatomic and Surgical Pathology (ADASP)


> Raouf E Nakhleh, MD Mayo Clinic Florida















### Introduction

- The CAP and ADASP convened an expert panel to systematically review published documents and develop an evidence-based guideline to help define the role of case reviews in surgical pathology and cytology.
- The panel focused on the contribution of case reviews to error detection and prevention of interpretive diagnostic errors









## **Expert Panel**

#### Co-chairs

Raouf Nakhleh, MD, **CAP** Vania Nosé, MD, PhD, **ADASP** 

#### **Expert Panel**


Tamera J. Lillemoe, MD Douglas C. McCrory, MD, MPH Frederick A. Meier, MD Christopher N. Otis, MD Scott R. Owens, MD Stephen S. Raab, MD Andrew A. Renshaw, MD Roderick R. Turner, MD


#### **Advisory Panel**

Timothy C. Allen, MD, JD Lawrence J. Burgart, MD Patrick L. Fitzgibbons, MD Jeffrey L. Myers, MD


#### Staff (CAP)


Lisa Fatheree, SCT(ASCP), Director Carol Colasacco, MLIS, SCT(ASCP), Medical Librarian Christina Ventura, MLS(ASCP), Guideline Development Manager








| Inclusion                                       | Exclusion  |
|---|--|
| Surgical pathology or cytopathology studies     | Clinical pathology studies                         |
| Original research addressing<br>targeted review | Studies focused on pre-analytic specimen processes |
| English language articles                       | Non-English studies                                |
| All study types were initially included         | Animal studies                                     |


















|   |                       |   |                             | mary of Stu  |  |
|---|-----------------------|---|-----------------------------|--|--|
| Study type  | Discrepancy rates (%) |   | Major Discrepancy rates (%) |  |  |
|   | No. of studies        | Median (25 <sup>th</sup> -75 <sup>th</sup><br>percentile) | No. of studies              | Median (25 <sup>th</sup> – 75 <sup>th</sup><br>percentile) |  |
| All studies   | 116                   | 18.3 (7.5-34.5)   | 78                          | 5.9 (2.1-10.5)   |  |
| Surgical<br>pathology                                       | 84                    | 18.3 (7.5-37.4)   | 63                          | 6.3 (1.9-10.6)   |  |
| Cytology  | 19                    | 24.8 (17.4-38.8)  | 11                          | 4.3 (2.8 - 7.5)  |  |
| Both  | 13                    | 9.1 (6.7 - 15.8)  | 11                          | 5.9 (3.3 - 8.7)  |  |
| Multi-organ   | 43                    | 9.1 (3.8-18.7)  | 42                          | 3.9 (1.1-7.4)  |  |
| Single-organ*   | 73                    | 25.2 (14.0-43.7)  | 36                          | 8.0 (3.7-15.8)   |  |
| Internal**  | 35                    | 10.9 (3.8 - 17.6)   | 22                          | 1.2 (0.30-3.1)   |  |
| External  | 79                    | 23.0 (10.6-40.2)  | 56                          | 7.4 (4.6-14.7)   |  |
| *Single-organ refers to stud<br>with regard to organs studi |                       | on one organ or organ system; m                           | ulti-organ refe             | rs to studies that are not limited                         |  |














| Prospective vs. Retrospective Review |                          |                         |                                  |                             |  |  |
|--------------------------------------|--------------------------|-------------------------|----------------------------------|-----------------------------|--|--|
| Studies                              | VE VS. R<br>Setting      | etrospect<br>Comparison | IVE REVIO<br>Prospective<br>Rate | ⊖W<br>Retrospective<br>Rate |  |  |
| Renshaw<br>and Gould,<br>2006        | Single<br>Institution    | Subgroup<br>cohort      | D 4.8%<br>A 0.0%                 | 7.2%<br>0.5%                |  |  |
| Novis, 2005                          | Single<br>Institution    | Historical<br>cohort    | A 0.6%                           | 1.3%                        |  |  |
| Lind et al,<br>1995                  | Single<br>Institution    | Historical<br>cohort    | D 14.1%<br>SD 1.2%               | 13.0%<br>1.7%               |  |  |
| Owens et al,<br>2010                 | Single<br>Institution    | Historical<br>cohort    | D 2.3%<br>SD 0.0%                | 3.4%<br>0.2%                |  |  |
| Nakhleh et<br>al, 1998               | Multiple<br>Institutions | Review<br>method        | A 0.12%                          | 0.16%                       |  |  |
















































| s of Stu<br>ent | dies Addre  | ssing Dia   | gnostic   |
|-----------------|---|---|---|
| Organ           | Disease   | Decision  | Карра   |
| Esophagus       | Barrett's<br>Esophagus                              | 3 cat (ND,<br>IND/LGD<br>HGD/AC)  | 0.25-0.27   |
| Uterus          | Atypical<br>endometrial<br>hyperplasia              | Atypical<br>hyperplasia vs.<br>others   | 0.4<br>(0.34-0.43)  |
| Prostate        | Adenocarcinoma                                      | Gleason grade   | 0.49  |
| Thyroid         | Malignant   | Yes/no  | 0.55  |
| Breast          | DCIS  | Nuclear grade<br>Margin status<br>Tumor size  | 0.7<br>0.74<br>0.87   |
|                 | Organ<br>Esophagus<br>Uterus<br>Prostate<br>Thyroid | OrganDiseaseSoophagusBarrett's<br>EsophagusUterusAtypical<br>endometrial<br>hyperplasiaProstateAdenocarcinomaThyroidMalignant | OrganDiseaseDecisionEsophagusBarrett's<br>Esophagus3 cat (ND,<br>IND/LGD<br>HGD/AC)UterusAtypical<br>endometrial<br>hyperplasiaAtypical<br>hyperplasia vs.<br>othersProstateAdenocarcinomaGleason gradeThyroidMalignantYes/noBreastDCISNuclear grade<br>Margin status |





- Identify and use optimal method of review
- Measure sensitivity of review process
- Standardize criteria for review method,
- Standardize definition of error
- Define expected ranges of discrepancy and error
- Define methods to verify poor performance

